Concordance of amyloid PET and CSF metabolic biomarkers in Alzheimer's disease and how to improve it: data from the Czech Brain Ageing Study

被引：0
|
作者：
Cerman, J.
Laczo, J. [1 ,2 ]
Vyhnalek, M. [1 ,2 ]
Belohlavek, O. [3 ,4 ]
Malinovska, J. [1 ,2 ]
Sheardova, K. [5 ]
Hort, J. [1 ,2 ]
机构：
[1] Charles Univ Prague, Fac Med 2, Dept Neurol, Prague, Czech Republic
[2] Motol Univ Hosp, Prague, Czech Republic
[3] Na Homolce Hosp, Dept Nucl Med, Brno, Czech Republic
[4] Na Homolce Hosp, PET Ctr, Brno, Czech Republic
[5] St Annes Univ Hosp, ICRC, Neurol Dept 1, Brno, Czech Republic
来源：
EUROPEAN JOURNAL OF NEUROLOGY | 2018年 / 25卷
关键词：
D O I：
暂无
中图分类号：
R74 [神经病学与精神病学];
学科分类号：
摘要：
EPR1002
引用
收藏
页码：277 / 277
页数：1
相关论文
共 50 条
  • [1] Agreement of amyloid PET and CSF biomarkers for Alzheimer's disease on Lumipulse
    Alcolea, Daniel
    Pegueroles, Jordi
    Munoz, Laia
    Camacho, Valle
    Lopez-Mora, Diego
    Fernandez-Leon, Alejandro
    Le Bastard, Nathalie
    Huyck, Els
    Nadal, Alicia
    Olmedo, Veronica
    Sampedro, Frederic
    Montal, Victor
    Vilaplana, Eduard
    Clarimon, Jordi
    Blesa, Rafael
    Fortea, Juan
    Lleo, Alberto
    ANNALS OF CLINICAL AND TRANSLATIONAL NEUROLOGY, 2019, 6 (09): : 1815 - 1824
  • [2] Use of amyloid PET imaging and cerebrospinal fluid biomarkers in clinical practice: Data from the Czech brain ageing study
    Cerman, J.
    Laczo, J.
    Vyhnalek, M.
    Matoska, V.
    Kaplan, V.
    Ferda, J.
    Belohlavek, O.
    Sheardova, K.
    Hort, J.
    EUROPEAN JOURNAL OF NEUROLOGY, 2017, 24 : 449 - 449
  • [3] Dissociation of amyloid biomarkers in PET and CSF in Alzheimer's disease: a case report
    Schroeter, Matthias L.
    Tiepolt, Solveig
    Marschhauser, Anke
    Thoene-Otto, Angelika
    Hoffmann, Karl-Titus
    Barthel, Henryk
    Obrig, Hellmuth
    Sabri, Osama
    BMC NEUROLOGY, 2015, 15
  • [4] Dissociation of amyloid biomarkers in PET and CSF in Alzheimer’s disease: a case report
    Matthias L. Schroeter
    Solveig Tiepolt
    Anke Marschhauser
    Angelika Thöne-Otto
    Karl-Titus Hoffmann
    Henryk Barthel
    Hellmuth Obrig
    Osama Sabri
    BMC Neurology, 15
  • [5] Considerations in the clinical use of amyloid PET and CSF biomarkers for Alzheimer's disease
    Leuzy, Antoine
    Bollack, Ariane
    Pellegrino, Daniela
    Teunissen, Charlotte E.
    La Joie, Renaud
    Rabinovici, Gil D.
    Franzmeier, Nicolai
    Johnson, Keith
    Barkhof, Frederik
    Shaw, Leslie M.
    Arkhipenko, Alexander
    Schindler, Suzanne E.
    Honig, Lawrence S.
    Moscoso Rial, Alexis
    Scholl, Michael
    Zetterberg, Henrik
    Blennow, Kaj
    Hansson, Oskar
    Farrar, Gill
    ALZHEIMERS & DEMENTIA, 2025, 21 (03)
  • [6] CSF Biomarkers for Amyloid and Tau Pathology in Alzheimer's Disease
    Rosenmann, Hanna
    JOURNAL OF MOLECULAR NEUROSCIENCE, 2012, 47 (01) : 1 - 14
  • [7] CSF Biomarkers for Amyloid and Tau Pathology in Alzheimer's Disease
    Hanna Rosenmann
    Journal of Molecular Neuroscience, 2012, 47 : 1 - 14
  • [8] Detailed comparison of amyloid PET and CSF biomarkers for identifying early Alzheimer disease
    Palmqvist, Sebastian
    Zetterberg, Henrik
    Mattsson, Niklas
    Johansson, Per
    Minthon, Lennart
    Blennow, Kaj
    Olsson, Mattias
    Hansson, Oskar
    NEUROLOGY, 2015, 85 (14) : 1240 - 1249
  • [9] How well do plasma Alzheimer's disease biomarkers reflect the CSF amyloid status?
    Hazan, Jemma
    Abel, Emily
    Grilo, Miguel Rosa
    Alawode, Deborah
    Laranjinha, Ines
    Heslegrave, Amanda J.
    Liu, Kathy Y.
    Schott, Jonathan M.
    Howard, Robert
    Zetterberg, Henrik
    Fox, Nick C.
    JOURNAL OF NEUROLOGY NEUROSURGERY AND PSYCHIATRY, 2024,
  • [10] Fluid and PET biomarkers for amyloid pathology in Alzheimer's disease
    Cohen, Ann D.
    Landau, Susan M.
    Snitz, Beth E.
    Klunk, William E.
    Blennow, Kaj
    Zetterberg, Henrik
    MOLECULAR AND CELLULAR NEUROSCIENCE, 2019, 97 : 3 - 17
12345